NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression- free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The BRAFTOVI regimen demonstrated a statistically sig. ...

Core Insights - Pfizer Inc. announced positive results from Cohort 3 of the BREAKWATER trial, which evaluates the efficacy of BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFIRI in patients with untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation [1] Group 1 - The BREAKWATER trial is pivotal for assessing the BRAFTOVI combination regimen [1] - The study focuses on patients with previously untreated metastatic colorectal cancer [1] - The combination includes BRAFTOVI, cetuximab (marketed as ERBITUX®), and FOLFIRI (fluorouracil, leucovorin, and irinotecan) [1]